Kenvue

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kenvue (KVUE) reports strong Q2 earnings, eyes China growth

Kenvue's Q2 performance showcased robust net sales, organic growth, and strategic investments in key segments. The company's focus on consumer trust, supply chain enhancements, and capital allocation strategy underpin its resilience. Challenges include managing inflationary pressures and sustaining growth post-COVID, but opportunities in China and ongoing investments position Kenvue for future success.

Kenvue (KVUE) reports solid Q3 performance amidst segment challenges

Kenvue (KVUE) delivered a solid Q3 performance, showcasing strength in key segments despite challenges in others.
The company's strategic initiatives, focus on innovation, and outlook for growth opportunities position it well for future success.
Efforts to address challenges in specific segments and capitalize on opportunities demonstrate a proactive approach to sustaining growth and profitability.
Overall positive outlook on third-quarter results reflects the company's strong model, portfolio, and cash flow generation capabilities.

Kenvue reports mixed 2023 performance, focuses on growth strategies

Kenvue's 2023 performance saw organic growth but faced challenges in specific segments, leading to adjustments for 2024. The company aims to drive growth through operational efficiencies, increased brand investments, and a focus on consumer engagement. Challenges in U.S. in-store execution prompted a recovery plan and leadership changes.

Kenvue surpasses Q1 expectations, eyes China growth amid challenges

Kenvue's Q1 performance exceeded expectations, driven by key segments and brands.
Strategic focus on cost optimization, operational efficiency, and brand impact.
Challenges include stabilizing declining segments and managing hyperinflation impact.
Opportunities lie in growing China business, operational reinvention, and new leadership.

Kenvue reports solid Q2 performance and optimistic outlook for 2024

Kenvue's Q2 performance reflects steady growth and improved profitability, driven by strategic initiatives and strong brand performance. While cost management and increased marketing spend pose challenges, the company's focus on brand investment and long-term value creation offers promising opportunities for future growth and shareholder returns.

Kenvue reports Q3 growth, tackles Skin Health challenges, eyes savings

Kenvue's Q3 performance showed organic growth and strong financial metrics.
While facing challenges in the Skin Health segment, the company is focusing on recovery.
Investments in marketing and efficiency improvements highlight growth opportunities.
Executives addressed key questions on guidance, inventory levels, and growth strategies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kenvue, Inc. is a consumer health company. It operates through the following business segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care and hair, sun and others. The Essential Health segment focuses on oral care, baby care, women's health and wound care. The company was founded on February 23, 2022 and is headquartered in Skillman, NJ.

Kenvue CEO Thibaut Mongon said the spinoff's portfolio of brands, which includes Band-Aid, Tylenol and Neutrogena, has "ample opportunity" to grow.

Kenvue CEO looks to brand, product innovation to drive growth after IPO

Kenvue Inc. is defensive and resilient to macro shocks. The company owns a portfolio of well-established brands.

Kenvue Stock Surges On Trading Debut

Johnson & Johnson

2023 has been a pretty slow year as far as initial public offerings go, but pharmaceutical giant Johnson & Johnson ( JNJ , Financial) bucked the trend on Thursday by offering its consumer health division Kenvue (KENV) as an IPO. Priced at about $22 per share and set to raise approximately $3.8 billion for J&J, the IPO values the new pure-play consumer health company at a total of $41 billion.

J&J's Kenvue: Unlocking Value in a Stagnant Market

Johnson & Johnson's consumer healthcare spinoff has made the biggest U.S. initial public offering (IPO) since 2021. Kenvue, which includes Band-Aid and several other well-known consumer brands that had been part of Johnson & Johnson, raised $3.8 billion in an IPO that valued it at $41 billion Thursday (May 4), CNBC reported Thursday.

Johnson & Johnson Spinoff Kenvue Valued at $41 Billion in IPO

At its expected valuation, KVUE looks fully valued and does not provide investors with much upside potential.

Kenvue IPO: Profitable Company, Expensive Stock

Kenvue Inc. shares KVUE, +16.16% were cheered in their Wall Street debut Thursday, as the Johnson & Johnson JNJ, -0.55% spinoff, with consumer brands including Tylenol, Band-Aid and Listerine, saw it's stock open 16.0% above its initial public offering price. Kenvue raised $3.8 billion as it said late Wednesday that it sold 172.8 million shares in the IPO, up from previous expectations of 151.2 million shares, at $22 a share, which was at the higher end of the expected pricing range of between $20 and $23 a share.

Kenvue stock opens 16% above IPO, valuing the company at $47.7 billion

Kenvue's debut is the biggest U.S. IPO since EV maker Rivian went public in 2021.

J&J's consumer health spinoff Kenvue opens at $25.53, a 16% jump, in public market debut

Johnson & Johnson (NYSE:JNJ)'s consumer health unit Kenvue Inc just priced the biggest US IPO since 2021, in a spot of welcome news for capital markets.  The spinoff is expected to achieve a valuation of $47 billion when it debuts on the NYSE on Thursday, with shares priced at $22 apiece but expected to open roughly 14% above that.

Johnson & Johnson spinoff Kenvue prices largest IPO since 2021

Johnson & Johnson rips off Band-Aid and spits out Listerine in a bid to boost margins.

Johnson & Johnson Spins Off Kenvue in Biggest IPO Haul Since 2021

Kenvue (NYSE: KVUE ) stock is set to start trading today as the company completes its spinoff from Johnson & Johnson (NYSE: JNJ ). Let's go over all of the details investors need to know about Kenvue going public today below!

KVUE Stock Alert: 10 Things to Know as Kenvue Starts Trading

Kenvue, which owns brands including Tylenol, Band-Aid, and Neutrogena, will begin trading Thursday. Shares were priced higher than an earlier range.

J&J Consumer-Health IPO Stock Kenvue to Raise $3.8 Billion

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) ("Kenvue") will begin trading today on the New York Stock Exchange under the ticker symbol “KVUE”.

Kenvue to Begin Trading on the New York Stock Exchange

A unit of Johnson & Johnson is headed for the biggest initial public offering in more than a year after its shares were priced near the top of the expected range Wednesday evening.

Johnson & Johnson's Kenvue IPO to command valuation of more than $40 billion in biggest public debut since 2021

NEW BRUNSWICK, N.J. & SKILLMAN, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) and Kenvue Inc. (“Kenvue”), a wholly owned subsidiary of Johnson & Johnson, today announced the pricing of Kenvue's upsized initial public offering (“IPO”) of 172,812,560 shares of Kenvue's common stock at a price to the public of $22.00 per share. In addition, Kenvue has granted the underwriters a 30-day option to purchase up to an additional 25,921,884 shares of its common stock to cover over-allotmen.

Johnson & Johnson and Kenvue Announce Pricing of Upsized Kenvue Inc. Initial Public Offering

The listing of the Tylenol maker would be by far the biggest initial public offering so far this year.

J&J Prices Consumer Unit IPO at $22 a Share

Johnson & Johnson (NYSE: JNJ ) will spin out its consumer health unit as Kenvue tomorrow, May 4. The stock will trade on the NYSE under the symbol KVUE.

KVUE Stock: Should You Buy Into the Kenvue IPO?

Johnson & Johnson's consumer health company Kenvue is expected to hit the initial public offering market this week and mark the largest deal since late 2021.

J&J's Kenvue spinoff to hit IPO market this week in the biggest deal since late 2021

One of the season's most hotly anticipated initial public offerings (IPOs) is about to hit the market. Kenvue is a planned spinoff from Johnson & Johnson (NYSE: JNJ ), and the company is set to begin trading soon.

KVUE Stock IPO: When Does Kenvue Go Public? What Is the Kenvue IPO Price Range?

BranchOut Food Inc/OR

Nature Wood Group Ltd

Interactive Strength Inc

The week's news was led by J&J's consumer health unit Kenvue, which set terms for its $3.3 billion listing on Monday. Six IPOs submitted initial filings this past week.

US IPO Weekly Recap: J&J Spin-Off Kenvue Launches Billion-Dollar Deal In A 1 IPO Week

IPO Update: Kenvue Seeks $3.25 Billion IPO.

IPO Update: Kenvue Seeks $3.25 Billion IPO

Are signs of life emerging from the moribund IPO market? If Johnson & Johnson (NYSE:JNJ)'s corporate advisors are correct, then, yes, possibly.

Does Johnson & Johnson's Kenvue IPO signal signs of life for US IPO market?

Johnson & Johnson JNJ expects to raise roughly $3 billion in an initial public offering of its consumer-health unit. In a filing with the Securities and Exchange Commission made public Monday afternoon, Johnson & Johnson said it expects to sell more than 151 million shares in the IPO at a price of $20 to $23, which would raise roughly $3.25 billion at the midpoint price of $21.50.

Johnson & Johnson aims to raise $3 billion in Kenvue IPO

Johnson & Johnson will price shares of its consumer-health spinoff Kenvue at $20 to $23 in an initial public offering later this year. J&J said it launched a roadshow for the IPO of more than 151 million shares of common stock.

Johnson & Johnson to price shares of consumer spinoff Kenvue at $20 to $23 in IPO

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that Kenvue Inc. (“Kenvue”), a wholly owned subsidiary of Johnson & Johnson comprising its Consumer Health Business, has launched a roadshow for the initial public offering (“IPO”) of 151,204,000 shares of its common stock. Kenvue expects to grant the underwriters a 30-day option to purchase up to an additional 22,680,600 shares of its common stock to cover over-allotments, if any. The IPO price is curre.

Johnson & Johnson Announces Launch of Kenvue Inc. IPO Roadshow

J&J's consumer health unit Kenvue aims to raise $3.5 billion or more in the initial public offering, sources told the Wall Street Journal.

News for Kenvue Stock (KVUE)